Terlipressin已经经受住了时间的考验:临床概述2020年和未来的观点。

文章的细节

引用

复制到剪贴板

Kulkarni AV,阿拉伯JP, Premkumar M,贝尼特斯C, Tirumalige Ravikumar年代,Kumar P,沙玛,Reddy DN, Simonetto哒,饶PN

Terlipressin已经经受住了时间的考验:临床概述2020年和未来的观点。

肝脏Int。2020年12月,40 (12):2888 - 2905。doi: 10.1111 / liv.14703。

PubMed ID

33065772 (在PubMed

]

文摘

作用于血管的药物形式的主要治疗肝脏疾病的两个最重要的并发症:肝肾综合征(小时)和急性静脉曲张的流血(真空断路)。累积证据支持使用在肝硬化,terlipressin推荐了小时的管理和真空断路。然而,由于安全问题,terlipressin没有通过食品和药物管理局(FDA)直到现在。在这次审查中,我们讨论了药理学和主要治疗进展的安全性和有效性研究terlipressin在肝硬化患者尤其是专注于现有迹象表明真空断路和小时和审查新数据扩大肝脏疾病的迹象。确定本文的引用从PUBMED网等术语“terlipressin”,“肝肾综合症,”“esophagal和胃静脉曲张,”“腹水”和“肝硬化”。Terlipressin, a synthetic analogue of vasopressin, was introduced in 1975 to overcome the adverse effects of vasopressin. Terlipressin is an effective drug for HRS reversal in patients with liver cirrhosis and acute-on-chronic liver failure. There is documented mortality benefit with terlipressin therapy in HRS and AVB. Adverse effects are common with terlipressin and need to be monitored strictly. There is some evidence to support the use of this drug in refractory ascites, hepatic hydrothorax, paracentesis-induced circulatory dysfunction and perioperatively during liver transplantation. However, terlipressin is not yet recommended for such indications. In conclusion, terlipressin has stood the test of time with expanding indications and clear prerequisites for clinical use. Our review warrants a fresh perspective on the efficacy and safety of terlipressin.

beplay体育安全吗DrugBank数据引用了这篇文章

药物

Terlipressin